GeneDx Holdings Corp.
GeneDx Holdings Corp. is a U.S.-based genomics diagnostics and data company focused on exome and genome sequencing for rare disease, hereditary risk, and cancer. It combines clinical testing, interpretation software, and a proprietary dataset to help clinicians reach faster, more actionable genetic diagnoses, while also monetizing data, bio-pharma programs, and software subscriptions through Fabric Genomics.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical exome and genome sequencing tests and related diagnostic reports sold to healthcare providers and payors.
Fabric Genomics software subscriptions plus interpretation and consulting services for genomic workflows.
Data licensing, research collaborations, and bio-pharma programs built on the GeneDx dataset.
Newborn screening products, information services, and other smaller revenue streams.
Products
Reported · share of revenue- Diagnostic Test Third Party Insurance80.7 %
- Diagnostic Test Institutional Customers16.4 %
- Other2.5 %
- Diagnostic Test Self Pay0.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
GeneDx sells primarily into the healthcare system, with payment coming from third-party payors, patients, and business-to-business partners. Its core buyers are clinicians and institutions that need genetic testing and interpretation for rare disease, hereditary risk, and cancer cases, while research and biopharma customers use the company’s dataset and software capabilities.
Insurers and managed care organizations reimburse diagnostic test reports and strongly influence pricing and volume.
Hospitals, genomic centers, and physicians order exome and genome tests to diagnose rare and complex conditions.
Labs buy software subscriptions and interpretation tools to support genomic workflows and reporting.
Academic and research customers use data, analysis, and consulting services for discovery and studies.
Drug developers use the GeneDx dataset and collaboration programs to support target discovery and evidence generation.
Strategy
GeneDx is investing in platform innovation to expand beyond a pure diagnostic testing model into software, data, and interpretation services. The strategy centers on growing exome and genome volumes, improving reimbursement and test mix, and using acquisitions such as Fabric Genomics to deepen AI-enabled interpretation and broaden customer reach.
These tests are the main revenue engine and benefit from higher reimbursement and better economics.
Recurring software and services can diversify revenue beyond diagnostic reports.
The proprietary dataset can support research partnerships and higher-margin adjacent revenue.
Geography
GeneDx is overwhelmingly U.S.-centric, with substantially all revenue tied to domestic diagnostic testing and healthcare reimbursement. Management disclosed that about 1.5% of revenue currently comes from referral sources outside the United States, but it expects international revenue to grow over time as exome and genome sequencing adoption expands.
Risks
GeneDx faces reimbursement, adoption, and competitive risks because most revenue depends on diagnostic testing and payor coverage. It also has integration and execution risk from acquisitions, plus exposure to regulatory, legal, and accounting judgments tied to complex contracts, contingent liabilities, and fair value estimates.
- Reimbursement pressureImpact: HighLikelihood: Medium
Diagnostic test revenue depends heavily on third-party payor coverage and pricing decisions.
Exposure: Exome and genome sequencing reimbursement
- Competitive intensityImpact: HighLikelihood: Medium
The company competes with specialty labs, academic centers, and informatics providers.
Exposure: Clinical genetic testing and interpretation
- Acquisition integration riskImpact: MediumLikelihood: Medium
Fabric Genomics and any future deals may be difficult to integrate and may not deliver expected benefits.
Exposure - Revenue timing and contract variabilityImpact: MediumLikelihood: Low
Collaboration and service agreements can fluctuate with delivery patterns, milestones, and cost estimates.
Exposure - Legal and contingent liability exposureImpact: MediumLikelihood: Low
The company has settlement obligations and fair value changes that can affect earnings and cash needs.
Exposure: Payor settlement and contingent liabilities
Accounting
Judgemental itemsDifferent service lines may recognize revenue at different times, affecting quarterly comparability.
Impact: Can shift reported revenue between periods
Changes in valuation assumptions can create large non-cash gains or losses.
Impact: Impacts net income and non-operating results
The company has payor-related settlement obligations that require accrual and cash planning.
Impact: Affects liabilities, cash flow, and earnings
Growth in test volumes and reimbursement rates influences collectability and working capital.
Impact: Affects operating cash flow and revenue realization
Similar listed companies
Publicly listed companies with a comparable business focus.
Insight Molecular Diagnostics Inc.
IMDX · In Vitro & In Vivo Diagnostic Substances
10x Genomics, Inc.
TXG · Laboratory Analytical Instruments
10x Genomics is a life sciences tools company that sells integrated workflows for high-resolution analysis of biological samples, combining instruments, proprietary consumables, and bundled software.
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Ginkgo Bioworks Holdings, Inc.
DNA · Biological Products, (No Diagnostic Substances)
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
Myriad Genetics, Inc
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
Last updated: 24/09/2026